Analytical Data
-
Gene name
FcgBP
- Application
-
Alternative Names
FC(GAMMA)BP; IgG Fc Binding Protein; Human Fc Gamma BP; Fcgamma-binding protein antigen
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9Y6R7
-
Expression Region
Cys5176~Ala5344
-
Molecular Weight
20kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FcgBP, or Fc gamma binding protein, is a critical component in the immune response, playing a significant role in modulating the activities of antibodies and immune complexes. Understanding FcgBP is vital due to its implications in various diseases, including autoimmune disorders and infections. Research on recombinant FcgBP proteins has gained momentum as these proteins can help elucidate the mechanisms of antibody action and provide insights into potential therapeutic applications. By studying the recombinant form of FcgBP, scientists aim to uncover its binding affinities, structural properties, and interactions with various Fc receptors. This research is invaluable for developing targeted therapies that can enhance immune responses or inhibit pathologies driven by dysregulated immune functions. Recombining FcgBP with other immunotherapeutic agents may also lead to innovative strategies for treating conditions characterized by excessive inflammation or diminished immune efficacy. Overall, the exploration of recombinant FcgBP proteins stands at the intersection of immunology and therapeutic development, offering a promising avenue for advancing our understanding of immune system dynamics and enhancing clinical outcomes in various health conditions.
